{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T11:22:51Z","timestamp":1787656971319,"version":"build-2736575974"},"reference-count":90,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T00:00:00Z","timestamp":1770422400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T00:00:00Z","timestamp":1770422400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Psychopharmacology"],"published-print":{"date-parts":[[2026,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Major Depressive Disorder (MDD) is a common and debilitating condition. Current treatments fail to provide adequate relief in roughly one-third of individuals, resulting in treatment-resistant depression (TRD). Ketamine has emerged as a promising intervention for TRD, offering rapid and sustained antidepressant effects. However, benefits often require maintenance dosing, and long-term outcomes remain unclear. This has promoted interest in adjunctive approaches such as ketamine-assisted psychotherapy (KAP), which combines ketamine with structured psychological support.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A comprehensive literature search was conducted via the OVID platform using Embase, Medline, Global Health, and APA PsycInfo. Keyword clusters related to \u201cKetamine,\u201d \u201cDiagnosis,\u201d and \u201cPsychotherapy\u201d yielded 768 results. Screening followed PRISMA guidelines, resulting in 11 studies meeting inclusion criteria.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The selected studies clustered into two thematic categories: structured, protocol-based interventions and individualized, experiential approaches. Across all studies, KAP was associated with reductions in depressive symptoms, with some improvements sustained up to six months. However, among the three studies with control groups, no significant differences were found between KAP and control conditions. Methodological heterogeneity\u2014including variability in treatment protocols, outcome measures, and study designs\u2014limits the ability to draw firm conclusions or identify mechanisms driving KAP\u2019s effects.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>KAP shows promise as a treatment for TRD, potentially offering meaningful and sustained symptom relief. However, limited evidence and methodological variability underscore the need for more rigorous research\u2014particularly randomized controlled trials\u2014to better understand its efficacy and mechanisms.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00213-026-07003-0","type":"journal-article","created":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T00:32:52Z","timestamp":1770424372000},"page":"1801-1817","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Effectiveness of ketamine-assisted psychotherapy as a treatment for treatment-resistant depression: a systematic review"],"prefix":"10.1007","volume":"243","author":[{"given":"Rebecca J.","family":"Simpson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8558-3396","authenticated-orcid":false,"given":"Mario F.","family":"Juruena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,7]]},"reference":[{"issue":"7","key":"7003_CR1","first-page":"566","volume":"2","author":"CG Abdallah","year":"2017","unstructured":"Abdallah CG, Averill CL, Salas R et al (2017) Prefrontal connectivity and glutamate transmission: relevance to depression pathophysiology and ketamine treatment. Biol Psychiatry Cogn Neurosci Neuroimaging 2(7):566\u2013574","journal-title":"Biol Psychiatry Cogn Neurosci Neuroimaging"},{"key":"7003_CR2","doi-asserted-by":"publisher","DOI":"10.1176\/appi.books.9780890425596","volume-title":"Diagnostic and statistical manual of mental disorders: DSM-V","author":"American Psychiatric Association","year":"2013","unstructured":"American Psychiatric Association (2013) Diagnostic and statistical manual of mental disorders: DSM-V, 5th edn. American Psychiatric Publishing, Washington D.C","edition":"5"},{"issue":"7","key":"7003_CR3","doi-asserted-by":"publisher","first-page":"e852","DOI":"10.4088\/JCP.17f11738","volume":"78","author":"C Andrade","year":"2017","unstructured":"Andrade C (2017) Ketamine for depression, 4: in what dose, at what rate, by what route, for how long, and at what frequency? J Clin Psychiatry 78(7):e852\u2013e857","journal-title":"J Clin Psychiatry"},{"key":"7003_CR4","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1111\/j.1476-5381.1983.tb11031.x","volume":"79","author":"NA Anis","year":"1983","unstructured":"Anis NA, Berry SC, Burton NR et al (1983) The dissociative anaesthetics, ketamine and phencyclidine, selectively reduce excitation of central mammalian neurones by N-methyl-aspartate. Br J Pharmacol 79:565\u2013575","journal-title":"Br J Pharmacol"},{"key":"7003_CR5","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-20190-4","volume":"11","author":"ED Ballard","year":"2020","unstructured":"Ballard ED, Zarate CA Jr (2020) The role of dissociation in ketamine\u2019s antidepressant effects. Nat Commun 11:6431","journal-title":"Nat Commun"},{"key":"7003_CR6","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2024-084844","volume":"14","author":"B Beaglehole","year":"2024","unstructured":"Beaglehole B, Porter R, Douglas K et al (2024) Protocol for a randomised controlled trial of ketamine versus ketamine and behavioural activation therapy for adults with treatment-resistant depression in the community. BMJ Open 14:e084844","journal-title":"BMJ Open"},{"issue":"47","key":"7003_CR7","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/S0006-3223(99)00230-9","volume":"15","author":"RM Berman","year":"2000","unstructured":"Berman RM, Cappiello A, Anand A et al (2000) Antidepressant effects of ketamine in depressed patients. Biol Psychiatry 15(47):351\u2013354","journal-title":"Biol Psychiatry"},{"key":"7003_CR8","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1007\/s00213-011-2233-4","volume":"215","author":"E Bjorkedal","year":"2011","unstructured":"Bjorkedal E, Flaten MA (2011) Interaction between expectancies and drug effects: an experimental investigation of placebo analgesia with caffeine as an active placebo. Psychopharmacology 215:537\u2013548","journal-title":"Psychopharmacology"},{"issue":"10","key":"7003_CR9","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1001\/jamapsychiatry.2022.2096","volume":"79","author":"MP Bogenschutz","year":"2022","unstructured":"Bogenschutz MP, Ross S, Bhatt S et al (2022) Percentage of heavy drinking days following Psilocybin-assisted psychotherapy vs placebo in the treatment of adult patients with alcohol use disorder. JAMA Psychiatr 79(10):953\u2013962","journal-title":"JAMA Psychiatr"},{"key":"7003_CR10","doi-asserted-by":"publisher","DOI":"10.1038\/s42003-023-05093-6","volume":"6","author":"I Brys","year":"2023","unstructured":"Brys I, Barrientos SA, Ward JE et al (2023) 5-HT2AR and NMDAR psychedelics induce similar hyper-synchronous states in the rat cognitive-limbic cortex-basal ganglia system. Commun Biol 6:737","journal-title":"Commun Biol"},{"key":"7003_CR11","doi-asserted-by":"publisher","first-page":"S67","DOI":"10.1016\/S0924-977X(16)70074-5","volume":"26","author":"RA Chesters","year":"2016","unstructured":"Chesters RA, Stone JM, Hughes E et al (2016) Translational neuroimaging reveals differential effects of chronic ketamine on brain macrostructure in humans and mice. Eur Neuropsychopharmacol 26:S67\u2013S68","journal-title":"Eur Neuropsychopharmacol"},{"issue":"S1","key":"7003_CR12","doi-asserted-by":"publisher","first-page":"S419","DOI":"10.1192\/j.eurpsy.2023.903","volume":"66","author":"P Chu","year":"2023","unstructured":"Chu P, Silverstone P, Hillier T et al (2023) A 28-Day, Randomized, Controlled, Singl-Blind, phase 2 study in Treatment-Resistant major depressive disorder (TRD) patients receiving intranasal Esketamine comparing addition of almond therapy TM with Treatment-as-Usual (TAU). Eur Psychiatry 66(S1):S419\u2013S420","journal-title":"Eur Psychiatry"},{"key":"7003_CR13","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.jad.2024.05.070","volume":"359","author":"M Ciharova","year":"2024","unstructured":"Ciharova M, Karyotaki E, Miguel C (2024) Amount and frequency of psychotherapy as predictors of treatment outcome for adult depression: a meta-regression analysis. J Affect Disord 359:92\u201399","journal-title":"J Affect Disord"},{"issue":"5","key":"7003_CR14","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1177\/0269881115581093","volume":"29","author":"A Cleare","year":"2015","unstructured":"Cleare A, Young AH, Anderson IM et al (2015) Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 2008 British Association for Psychopharmacology guidelines. J Psychopharmacol 29(5):459\u2013525","journal-title":"J Psychopharmacol"},{"key":"7003_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jad.2013.02.030","volume":"149","author":"P Cuijpers","year":"2013","unstructured":"Cuijpers P, Huibers M, Ebert DD et al (2013) How much psychotherapy is needed to treat depression? A metaregression analysis. J Affect Disord 149:1\u201313","journal-title":"J Affect Disord"},{"issue":"1","key":"7003_CR16","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1002\/wps.20089","volume":"13","author":"P Cuijpers","year":"2014","unstructured":"Cuijpers P, Sijbrandij M, Koole SL et al (2014) Adding psychotherapy to antidepressant medication in depression and anxiety disorders: a meta-analysis. World Psychiatry 13(1):56\u201367","journal-title":"World Psychiatry"},{"issue":"9","key":"7003_CR17","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1001\/jamapsychiatry.2019.1189","volume":"76","author":"EJ Daly","year":"2019","unstructured":"Daly EJ, Trivedi MH, Janik A et al (2019) Efficacy of Esketamine nasal spray plus oral antidepressant treatment for relapse prevention in patients with treatment-resistant depression: a randomised clinical trial. JAMA Psychiatry 76(9):893\u2013903","journal-title":"JAMA Psychiatry"},{"key":"7003_CR18","doi-asserted-by":"publisher","unstructured":"Dames S, Kryskow P, Walter C (2022) A Cohort-Based case report: the impact of Ketamine-Assisted therapy embedded in a community of practice framework for healthcare providers with PTSD and depression. Front Psychiatry 12. https:\/\/doi.org\/10.3389\/fpsyt.2021.803279","DOI":"10.3389\/fpsyt.2021.803279"},{"key":"7003_CR19","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1097\/ALN.0b013e3181ed09a2","volume":"113","author":"EF Domino","year":"2010","unstructured":"Domino EF, Warner DS (2010) Taming the ketamine tiger. Anesthesiology 113:678\u2013684","journal-title":"Anesthesiology"},{"issue":"2","key":"7003_CR20","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1080\/02791072.2019.1587556","volume":"51","author":"J Dore","year":"2019","unstructured":"Dore J, Turnipseed B, Dwyer S et al (2019) Ketamine assisted psychotherapy (KAP): patient demographics, clinical data and outcomes in three large practices administering ketamine with psychotherapy. J Psychoact Drugs 51(2):189\u2013198","journal-title":"J Psychoact Drugs"},{"key":"7003_CR21","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.2147\/JPR.S360733","volume":"15","author":"SJ Drozdz","year":"2022","unstructured":"Drozdz SJ, Goel A, McGarr M et al (2022) Ketamine assisted psychotherapy: a systematic narrative review of the literature. J Pain Res 15:1691\u20131706","journal-title":"J Pain Res"},{"key":"7003_CR22","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1186\/s12888-018-1679-x","volume":"18","author":"A Fekadu","year":"2018","unstructured":"Fekadu A, Donocik JG, Cleare AJ (2018) Standardisation framework for the Maudsley staging method for treatment resistance in depression. BMC Psychiatry 18:100","journal-title":"BMC Psychiatry"},{"issue":"4","key":"7003_CR23","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1037\/pst0000172","volume":"55","author":"C Fluckiger","year":"2018","unstructured":"Fluckiger C, Del Re AC, Wampold BE et al (2018) The alliance in adult psychotherapy: a Meta-Analystic synthesis. Psychotherapy 55(4):316\u2013340","journal-title":"Psychotherapy"},{"issue":"9","key":"7003_CR24","doi-asserted-by":"publisher","first-page":"371","DOI":"10.3928\/00485713-20220810-04","volume":"52","author":"FE Forcen","year":"2022","unstructured":"Forcen FE, Nyer M (2022) Ketamine with psychotherapy for the treatment of depression. Psychiatr Ann 52(9):371\u2013374","journal-title":"Psychiatr Ann"},{"key":"7003_CR25","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.jclinepi.2020.07.005","volume":"127","author":"TF Frandsen","year":"2020","unstructured":"Frandsen TF, Nielsen MFB, Lindhardt CL, Eriksen MB (2020) Using the full PICO model as a search tool for systematice reviews resulted in lower recall for some PICO elements. J Clin Epidemiol 127:69\u201375","journal-title":"J Clin Epidemiol"},{"key":"7003_CR26","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1016\/j.neuron.2007.01.008","volume":"53","author":"J Gonzales-Maeso","year":"2007","unstructured":"Gonzales-Maeso J, Weisstaub NV, Zhou M (2007) Hallucinogens recruit specific cortical 5-HT2A receptor-mediated signalling pathways to affect behaviour. Neuron 53:439\u2013452","journal-title":"Neuron"},{"key":"7003_CR27","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1007\/s00213-011-2358-5","volume":"218","author":"RR Griffiths","year":"2011","unstructured":"Griffiths RR, Johnson MW, Richards WA et al (2011) Psilocybin occasioned mystical-type experiences: immediate and persisting dose-related effect. Psychopharmacology 218:649\u2013665","journal-title":"Psychopharmacology"},{"key":"7003_CR28","doi-asserted-by":"publisher","unstructured":"Hartogsohn I (2017) Constructing drug effects: a history of set and setting. Drug Sci Policy Law 3. https:\/\/doi.org\/10.1177\/205032451668332","DOI":"10.1177\/205032451668332"},{"key":"7003_CR29","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1037\/hea0000499","volume":"36","author":"LC Howe","year":"2017","unstructured":"Howe LC, Goyer JP, Crum AJ (2017) Harnessing the placebo effect: exploring the influence of physician characteristics on placebo response. Health Psychol 36:1074\u20131082","journal-title":"Health Psychol"},{"key":"7003_CR30","doi-asserted-by":"publisher","unstructured":"Ingrosso G, Cleare AJ, Juruena MF (2024) Is there a risk of addiction to ketamine during the treatment of depression? A systematic review of available literature. J Psychopharmacol 39(1):49\u201365. https:\/\/doi.org\/10.1177\/02698811241303597","DOI":"10.1177\/02698811241303597"},{"key":"7003_CR31","doi-asserted-by":"crossref","unstructured":"Ioannidis JPA (2008) Effectiveness of antidepressants: an evidence myth constructed from a thousand randomized trials? Philosophy, Ethics, and Humanities in Medicine, 3 (14)","DOI":"10.1186\/1747-5341-3-14"},{"issue":"17","key":"7003_CR32","doi-asserted-by":"publisher","first-page":"3123","DOI":"10.1007\/s00213-015-3957-3","volume":"232","author":"JD Jett","year":"2015","unstructured":"Jett JD, Boley AM, Girotti M et al (2015) Antidepressant-like cognitive and behavioural effects of acute ketamine administration associated with plasticity in the ventral hippocampus to medial prefrontal cortex pathway. Psychopharmacology (Berl) 232(17):3123\u20133133","journal-title":"Psychopharmacology (Berl)"},{"key":"7003_CR33","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.jad.2022.07.030","volume":"315","author":"I Joneborg","year":"2022","unstructured":"Joneborg I, Lee Y, Di Vincenzo JD et al (2022) Active mechanisms of ketamine-assisted psychotherapy: a systematic review. J Affect Disord 315:105\u2013112","journal-title":"J Affect Disord"},{"key":"7003_CR34","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1146\/annurev-med-051322-120608","volume":"75","author":"JW Kim","year":"2024","unstructured":"Kim JW, Suzuki K, Kavalali ET et al (2024) Ketamine: mechanisms and relevance to treatment of depression. Annu Rev Med 75:129\u2013143","journal-title":"Annu Rev Med"},{"key":"7003_CR35","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2022.917199","volume":"13","author":"K Ko","year":"2022","unstructured":"Ko K, Knight G, Rucker JJ et al (2022) Psychedelics, mystical experience, and therapeutic efficacy: a systematic review. Front Psychiatry 13:917199","journal-title":"Front Psychiatry"},{"key":"7003_CR36","doi-asserted-by":"publisher","DOI":"10.1038\/s41398-023-02451-0","volume":"13","author":"J Kopelman","year":"2023","unstructured":"Kopelman J, Keller TA, Panny B et al (2023) Rapid neuroplasticity changes and response to intravenous ketamine: a randomised controlled trial in treatment-resistant depression. Transl Psychiatry 13:159","journal-title":"Transl Psychiatry"},{"issue":"9","key":"7003_CR37","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1046\/j.1525-1497.2001.016009606.x","volume":"16","author":"K Kroenke","year":"2001","unstructured":"Kroenke K, Spitzer RL, Williams JBW (2001) The PHQ-9 validity of a brief depression severity measure. J Gen Intern Med 16(9):606\u2013613","journal-title":"J Gen Intern Med"},{"issue":"1","key":"7003_CR38","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1300\/J020V09N01_09","volume":"9","author":"EM Krupitsky","year":"1992","unstructured":"Krupitsky EM, Grineko Y, Berkaliev TN et al (1992) The combination of psychedelic and aversive approaches in alcoholism treatment: the affective contra-attribution method. Alcohol Treat Q 9(1):99\u2013105","journal-title":"Alcohol Treat Q"},{"issue":"3","key":"7003_CR39","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1002\/brb3.37","volume":"2","author":"KA Leiknes","year":"2012","unstructured":"Leiknes KA, Jarosh-Von Schweder L, Hoie B (2012) Contemporary use and practice of electroconvulsive therapy worldwide. Brain Behav 2(3):283\u2013344","journal-title":"Brain Behav"},{"key":"7003_CR40","doi-asserted-by":"publisher","first-page":"11","DOI":"10.2147\/SAR.S15458","volume":"16","author":"JH Li","year":"2011","unstructured":"Li JH, Vicknasingam B, Cheung YW (2011) To use or not to use: an update on licit and illicit ketamine use. Subst Abuse Rehabilitation 16:11\u201320","journal-title":"Subst Abuse Rehabilitation"},{"issue":"5994","key":"7003_CR41","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1126\/science.1190287","volume":"329","author":"N Li","year":"2010","unstructured":"Li N, Lee B, Liu RJ et al (2010) mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists. Science 329(5994):959\u2013964","journal-title":"Science"},{"issue":"11","key":"7003_CR42","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1038\/s44220-023-00140-x","volume":"1","author":"TR Lii","year":"2023","unstructured":"Lii TR, Smith AE, Flohr JR (2023) Randomised trial of ketamine masked by surgical anaesthesia in patients with depression. Nat Ment Health 1(11):876\u2013886","journal-title":"Nat Ment Health"},{"issue":"6","key":"7003_CR43","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1097\/JCP.0000000000000229","volume":"34","author":"CH Lin","year":"2014","unstructured":"Lin CH, Lu MJ, Wong J et al (2014) Comparison of physician-rating and self-rating scales for patients with major depressive disorder. J Clin Psychopharmacol 34(6):716\u2013721","journal-title":"J Clin Psychopharmacol"},{"key":"7003_CR44","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.jad.2014.02.017","volume":"159","author":"DA Luckenbaugh","year":"2014","unstructured":"Luckenbaugh DA, Niciu MJ, Ionescu DF et al (2014) Do the dissociative side effects of ketamine mediate its antidepressant effects? J Affect Disord 159:56\u201361","journal-title":"J Affect Disord"},{"key":"7003_CR45","doi-asserted-by":"publisher","first-page":"3170","DOI":"10.1016\/j.celrep.2018.05.022","volume":"23","author":"C Ly","year":"2018","unstructured":"Ly C, Greb AC, Cameron LP et al (2018) Psychedelics promote structural and functional neural plasticity. Cell Rep 23:3170\u20133182","journal-title":"Cell Rep"},{"key":"7003_CR46","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1016\/j.jad.2020.09.007","volume":"277","author":"WS Marcatoni","year":"2020","unstructured":"Marcatoni WS, Akoumba BS, Wassef M et al (2020) A systematic review and meta-analysis of the efficacy of intravenous ketamine infusion for treatment resistant depression: January 2009- January 2019. J Affect Disord 277:831\u2013841","journal-title":"J Affect Disord"},{"key":"7003_CR47","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyg.2022.868103","volume":"13","author":"DS Mathai","year":"2022","unstructured":"Mathai DS, Mora V, Garcia-Romeu A (2022) Toward synergies of ketamine and psychotherapy. Front Psychol 13:868103","journal-title":"Front Psychol"},{"key":"7003_CR48","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1017\/S0033291714001603","volume":"45","author":"A McGirr","year":"2015","unstructured":"McGirr A, Berlim MT, Bond DJ et al (2015) A systematic review and meta-analysis of randomised, double-blind, placebo-controlled trials of ketamine in the rapid treatment of major depressive episodes. Psychol Med 45:693\u2013704","journal-title":"Psychol Med"},{"key":"7003_CR49","doi-asserted-by":"crossref","unstructured":"McIntyre RS, Rosenblat JD, Nemeroff CB et al (2021) Synthesising the Evidence for Ketamine and Esketamine in Treatment-Resistant Depression: An International Expert Opinion on the Available Evidence and Implementation, The American Journal of Psychiatry, 178 (5)","DOI":"10.1176\/appi.ajp.2020.20081251"},{"issue":"6","key":"7003_CR50","doi-asserted-by":"publisher","first-page":"2795","DOI":"10.1007\/s12325-021-01732-8","volume":"38","author":"EP McMullen","year":"2021","unstructured":"McMullen EP, Lee Y, Lipsitz O et al (2021) Strategies to prolong ketamine\u2019s efficacy in adults with treatment-resistant depression. Adv Ther 38(6):2795\u20132820","journal-title":"Adv Ther"},{"key":"7003_CR51","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1007\/978-3-319-04627-3_3","volume-title":"Guide to Assessment Scales in Major Depressive Disorder","author":"HJ Moller","year":"2014","unstructured":"Moller HJ (2014) Self-rating Scales. In: Alexopoulos G, Kasper S, Moller HJ, Moreno C (eds) Guide to Assessment Scales in Major Depressive Disorder. Springer, pp 23\u201334"},{"key":"7003_CR52","unstructured":"Montjoy JF (2022) Ketamine-assisted psychotherapy: Clinical outcomes and self-transcendence in depression and post-traumatic stress disorder (Order No. 29326399). Available from ProQuest One Academic; Publicly Available Content Database. (2715461912). Retrieved from https:\/\/www.proquest.com\/dissertations-theses\/ketamine-assisted-psychotherapy-clinical-outcomes\/docview\/2715461912\/se-2"},{"key":"7003_CR53","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1111\/j.1360-0443.2009.02761.x","volume":"105","author":"CJ Morgan","year":"2010","unstructured":"Morgan CJ, Muetzelfeldt L, Curran HV (2010) Consequences of chronic ketamine self-administration upon neurocognitive function and psychological wellbeing: a 1-year longitudinal study. Addiction 105:121\u2013133","journal-title":"Addiction"},{"key":"7003_CR54","doi-asserted-by":"crossref","unstructured":"Morrison RL, Singh J, Daly E et al (2024) Effect of Esketamine Nasal Spray on Cognition in Patients With Treatment-Resistant Depression: Results From Four Phase 3 Studies,\u00a0Int J Neuropsychopharmacol, 27(11)","DOI":"10.1093\/ijnp\/pyae046"},{"key":"7003_CR55","unstructured":"National Institute for Health and Care Excellence (NICE) (2022) Treatment summaries: depression, Visited 18\/07\/24, https:\/\/bnf.nice.org.uk\/treatment-summaries\/depression\/"},{"issue":"24","key":"7003_CR56","doi-asserted-by":"publisher","first-page":"14293","DOI":"10.1073\/pnas.2336126100","volume":"100","author":"CB Nemeroff","year":"2003","unstructured":"Nemeroff CB, Heim CM, Thase ME et al (2003) Differential responses to psychotherapy versus pharmacotherapy in patients with chronic forms of major depression and childhood. PNAS 100(24):14293\u201314296","journal-title":"PNAS"},{"key":"7003_CR57","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1016\/j.jad.2018.02.049","volume":"232","author":"MJ Niciu","year":"2018","unstructured":"Niciu MJ, Shovestul BJ, Jaso BA et al (2018) Features of dissociation differentially predict antidepressant response to ketamine in treatment-resistant depression. J Affect Disord 232:310\u2013315","journal-title":"J Affect Disord"},{"key":"7003_CR58","doi-asserted-by":"crossref","unstructured":"Nikolin S, Rodgers A, Schwaab A et al (2023) Ketamine for the treatment of major depression: a systematic review and meta-analysis,\u00a0eClin Med\u00a062 (102127)","DOI":"10.1016\/j.eclinm.2023.102127"},{"key":"7003_CR59","unstructured":"Office for National Statistics (ONS) (2022) Cost of living and depression in adults, great britain: 29 September to 23 October 2022, Visited 29\/07\/24, https:\/\/www.ons.gov.uk\/peoplepopulationandcommunity\/healthandsocialcare\/mentalhealth\/articles\/costoflivinganddepressioninadultsgreatbritain\/29septemberto23october2022#cost-of-living-and-depression-data"},{"key":"7003_CR60","doi-asserted-by":"publisher","unstructured":"Olson DE (2018) Psychoplastogens: a promising class of plasticity-promoting neurotherapeutics. J Exp Neurosci 12:1179069518800508. https:\/\/doi.org\/10.1177\/1179069518800508","DOI":"10.1177\/1179069518800508"},{"key":"7003_CR61","unstructured":"Oswin SL (2023) Differences in PHQ-9 depression severity between adults receiving ketamine or ketamine-assisted psychotherapy (Order No. 30248653), Available from ProQuest One Academic; Publicly Available Content Database. (2773152289). Retrieved from https:\/\/www.proquest.com\/dissertations-theses\/differences-phq-9-depression-severity-between\/docview\/2773152289\/se-2"},{"key":"7003_CR62","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, MckKenzie JE, Bossuyt PM et al (2021) The PRISMA 2020: an updated guideline for reporting systematic reviews. BMJ 372:71","journal-title":"BMJ"},{"key":"7003_CR63","doi-asserted-by":"publisher","first-page":"1856","DOI":"10.1001\/jama.1970.03170240060010","volume":"212","author":"WN Pahnke","year":"1970","unstructured":"Pahnke WN, Kurland AA, Unger S et al (1970) The experimental use of psychedelic (LSD) psychotherapy. JAMA 212:1856\u20131863","journal-title":"JAMA"},{"key":"7003_CR64","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1146\/annurev-psych-010418-102907","volume":"70","author":"KJ Petrie","year":"2019","unstructured":"Petrie KJ, Rief W (2019) Psychobiological mechanisms of placebo and nocebo effects: pathways to improve treatments and reduce side effects. Annu Rev Psychol 70:599\u2013625","journal-title":"Annu Rev Psychol"},{"key":"7003_CR65","volume":"14","author":"JL Phillips","year":"2023","unstructured":"Phillips JL, Blier P, Talbot J (2023) Sustaining the benefits of intravenous ketamine with behavioral activation therapy for depression: a case series. J Affect Disord Rep 14:100613","journal-title":"J Affect Disord Rep"},{"issue":"7","key":"7003_CR66","doi-asserted-by":"publisher","first-page":"2186","DOI":"10.1038\/s41591-025-03685-9","volume":"31","author":"C Pronovost-Morgan","year":"2025","unstructured":"Pronovost-Morgan C, Greenway KT, Rosean L, The ReSPCT Experts (2025) An international Delphi consensus for reporting of setting in psychedelic clinical trials. Nat Med 31(7):2186\u20132195","journal-title":"Nat Med"},{"key":"7003_CR67","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1186\/s40337-022-00588-9","volume":"10","author":"R Robinson","year":"2022","unstructured":"Robinson R, Lafrance A, Brendle M et al (2022) A case series of group-based ketamine-assisted psychotherapy for patients in residential treatment for eating disorders with comorbid depression and anxiety disorders. J Eat Disorders 10:65","journal-title":"J Eat Disorders"},{"issue":"10","key":"7003_CR68","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1176\/appi.ps.201900625","volume":"71","author":"EL Ross","year":"2020","unstructured":"Ross EL, Soeteman DI (2020) Cost-effectiveness of Esketamine nasal spray for patients with treatment-resistant depression in the United States. Psychiatr Serv 71(10):988\u2013997","journal-title":"Psychiatr Serv"},{"key":"7003_CR69","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.c332","volume":"340","author":"KF Schulz","year":"2010","unstructured":"Schulz KF, Altman DG, Moher D (2010) CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trial. BMJ 340:c332","journal-title":"BMJ"},{"issue":"6","key":"7003_CR70","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1192\/bjp.186.6.457","volume":"186","author":"B Sessa","year":"2005","unstructured":"Sessa B (2005) Can psychedelics have a role in psychiatry once again? Br J Psychiatry 186(6):457\u2013458","journal-title":"Br J Psychiatry"},{"key":"7003_CR71","doi-asserted-by":"publisher","DOI":"10.1038\/s41398-024-02973-1","volume":"14","author":"ZY Shen","year":"2024","unstructured":"Shen ZY, Gao DQ, Lv X et al (2024) A meta-analysis of the effects of ketamine on suicidal ideation in depression patients. Transl Psychiatry 14:248","journal-title":"Transl Psychiatry"},{"issue":"4","key":"7003_CR72","first-page":"287","volume":"34","author":"P Sos","year":"2013","unstructured":"Sos P, Klirova M, Novak T et al (2013) Relationship of ketamine\u2019s antidepressant and psychotomimetic effects in unipolar depression. Neuroendocrinol Lett 34(4):287\u2013293","journal-title":"Neuroendocrinol Lett"},{"key":"7003_CR73","first-page":"14898","volume":"366","author":"JAC Sterne","year":"2019","unstructured":"Sterne JAC, Savovic J, Page MJ et al (2019) ROB 2: a revised took for assessing risk of bias in randomised trials. BMJ 366:14898","journal-title":"BMJ"},{"key":"7003_CR74","doi-asserted-by":"publisher","DOI":"10.3389\/fnana.2022.795231","volume":"16","author":"JFM Strous","year":"2022","unstructured":"Strous JFM, Weeland CJ, Van Der Draai FA et al (2022) Brain changes associated with long-term ketamine abuse, a systematic review. Front Neuroanat 16:795231","journal-title":"Front Neuroanat"},{"issue":"5","key":"7003_CR75","first-page":"512","volume":"9","author":"B Szigeti","year":"2024","unstructured":"Szigeti B, Heifets BD (2024) Expectancy effects in psychedelic trials. Biol Psychiatry Cogn Neurosci Neuroimaging 9(5):512\u2013521","journal-title":"Biol Psychiatry Cogn Neurosci Neuroimaging"},{"issue":"5","key":"7003_CR76","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1080\/02791072.2023.2253798","volume":"56","author":"VWL Tsang","year":"2023","unstructured":"Tsang VWL, Ragazan DC, Kryskow P et al (2023) A pilot study comparing a community of practice program with and without concurrent ketamine-assisted therapy. J Psychoactive Drugs 56(5):627\u2013636","journal-title":"J Psychoactive Drugs"},{"key":"7003_CR77","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.19m12891","volume":"81","author":"E Wajs","year":"2020","unstructured":"Wajs E, Aluisio L, Holder R et al (2020) Esketamine nasal spray plus oral antidepressant in patients with treatment-resistant depression: assessment of long-term saety in a phase 3, open label study (SUSTAIN-2). J Clin Psychiatry 81:12891","journal-title":"J Clin Psychiatry"},{"key":"7003_CR78","unstructured":"Wenger-Treyner E, Wenger-Treyner B (2015) Introduction to Communities of Practice: a brief Overview of the concept and it\u2019s uses, available at: https:\/\/www.wenger-trayner.com\/introduction-to-communities-of-practice\/"},{"issue":"6","key":"7003_CR79","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1016\/j.biopsych.2018.09.004","volume":"85","author":"ST Wilkinson","year":"2019","unstructured":"Wilkinson ST, Holtzheimer PE, Gao S et al (2019b) Leveraging neuroplasticity to enhance adaptive learning: the potential for synergistic somatic-behavioural treatment combinations to improve clinical outcomes in depression. Biol Psychiatry 85(6):454\u2013465","journal-title":"Biol Psychiatry"},{"issue":"11","key":"7003_CR80","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1001\/jama.2019.10728","volume":"322","author":"ST Wilkinson","year":"2019","unstructured":"Wilkinson ST, Howard DH, Busch SH (2019a) Psychiatric practice patterns and barriers to the adoption of Esketamine. JAMA 322(11):1039\u20131040","journal-title":"JAMA"},{"key":"7003_CR81","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1159\/000517074","volume":"90","author":"ST Wilkinson","year":"2021","unstructured":"Wilkinson ST, Rhee TG, Joorman J et al (2021) Cognitive behavioural therapy to sustain the antidepressant effects of ketamine in Treatment-Resistant depression: a randomized clinical trial. Psychother Psychosom 90:318\u2013327","journal-title":"Psychother Psychosom"},{"key":"7003_CR82","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1159\/000457960","volume":"86","author":"ST Wilkinson","year":"2017","unstructured":"Wilkinson ST, Wright D, Fasula MK (2017) Cognitive behaviour therapy may sustain antidepressant effects of intravenous ketamine in treatment-resistant depression. Psychother Psychosom 86:162\u2013167","journal-title":"Psychother Psychosom"},{"key":"7003_CR83","unstructured":"Willen SSM (2024) A program evaluation of ketamine assisted psychotherapy for treatment-resistant depression (Order No. 30988153). Available from ProQuest One Academic, (2910064752), Retrieved from https:\/\/www.proquest.com\/dissertations-theses\/program-evaluation-ketamine-assisted\/docview\/2910064752\/se-2"},{"issue":"S1","key":"7003_CR84","first-page":"1","volume":"27","author":"JB Williams","year":"2012","unstructured":"Williams JB, Popp D, Kobak KA et al (2012) The power of expectation bias. Eur Psychiatry 27(S1):1","journal-title":"Eur Psychiatry"},{"issue":"12","key":"7003_CR85","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1176\/appi.ajp.2018.18020138","volume":"175","author":"NR Williams","year":"2018","unstructured":"Williams NR, Heifets BD, Blasey C et al (2018) Attenuation of antidepressant effects of ketamine by opioid receptor antagonism. Am J Psychiatry 175(12):1205\u20131215","journal-title":"Am J Psychiatry"},{"key":"7003_CR86","doi-asserted-by":"publisher","unstructured":"Wolfson P, Vaid G (2024) Ketamine-assisted psychotherapy, psychedelic methodologies, and the impregnable value to the subjective \u2013 a new and evolving approach. Front Psychiatry 15:1209419. https:\/\/doi.org\/10.3389\/fpsyt.2024.1209419","DOI":"10.3389\/fpsyt.2024.1209419"},{"key":"7003_CR87","unstructured":"World Health Organisation (WHO) (2023) Depressive disorder (depression), Visited 29\/07\/24, https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/depression"},{"key":"7003_CR88","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1016\/j.biopsych.2021.03.014","volume":"89","author":"H Wu","year":"2021","unstructured":"Wu H, Savalia NK, Kwan AC (2021) Ketamine for a boost of neural plasticity: how, but also when? Biol Psychiatry 89:1030\u20131032","journal-title":"Biol Psychiatry"},{"key":"7003_CR89","doi-asserted-by":"crossref","unstructured":"Yermus R, Bottos J, Bryson N et al (2024) Ketamine-Assisted Psychotherapy Provides Lasting and Effective Results in the Treatment of Depression, Anxiety, and Post-Traumatic Stress Disorder at 3 and 6 Months: Findings from a Large Retrospective Effectiveness Study, Psychedelic Medicine, 2 (2)","DOI":"10.1101\/2023.01.11.23284248"},{"issue":"8","key":"7003_CR90","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1001\/archpsyc.63.8.856","volume":"63","author":"CA Zarate","year":"2006","unstructured":"Zarate CA, Singh JB, Carlson PJ (2006) A randomised trial of an N-methyl-D-asparate antagonist in treatment-resistant major depression. Arch Gen Psychiatry 63(8):856\u2013864","journal-title":"Arch Gen Psychiatry"}],"container-title":["Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00213-026-07003-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00213-026-07003-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00213-026-07003-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T11:02:52Z","timestamp":1787655772000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00213-026-07003-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,7]]},"references-count":90,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["7003"],"URL":"https:\/\/doi.org\/10.1007\/s00213-026-07003-0","relation":{},"ISSN":["0033-3158","1432-2072"],"issn-type":[{"value":"0033-3158","type":"print"},{"value":"1432-2072","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,7]]},"assertion":[{"value":"15 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Human ethics and consent","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}]}}